Profound Medical Shares Rise 8.7% After FDA Gives Clearance for TULSA-PRO Thermal Boost
September 25 2023 - 4:01PM
Dow Jones News
By Stephen Nakrosis
Shares of Profound Medical rose in post-market trading on Monday
following the news that the U.S. Food and Drug Administration
granted 510(k) clearance for the Thermal Boost module for use in
conjunction with TULSA-PRO.
The stock rose 8.7% to $10.76 at 4:12 p.m. ET, and ended the
day's regular session down less than 1% at $9.92.
TULSA-PRO can be used by surgeons to ablate prostate tissue in
patients, including those with prostate cancer, the company said.
The company said it is developing software modules that will work
in conjunction with TULSA-PRO, covering a wide variety of prostate
disease states, shapes and sizes.
Section 510(k) of the Food, Drug and Cosmetic Act requires
manufacturers to give the FDA 90 days advance notice before they
can market a medical device.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 25, 2023 16:46 ET (20:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Profound Medical (TSX:PRN)
Historical Stock Chart
From Apr 2024 to May 2024
Profound Medical (TSX:PRN)
Historical Stock Chart
From May 2023 to May 2024
